Recent developments highlight CDT Equity's strategic moves to expand AI capabilities, strengthen intellectual property, and enter new markets, alongside corporate actions affecting its capital structure.

• CDT Equity announced plans to acquire a 20% stake in Sarborg to expand its AI offerings, enhancing its drug development capabilities [N1].
• The company completed a 1-for-8 reverse stock split effective October 10, 2025, as part of capital structure adjustments [N2].
• Conduit Pharmaceuticals filed its first patent for AZD5658 and new combination patents for AZD1656 and AZD5658 in collaboration with Sarborg Limited, strengthening its intellectual property portfolio [N3].
• Conduit Pharma entered a joint development agreement with Manoira to explore opportunities in the animal health market, expanding its therapeutic scope [N4].
• Conduit Pharma gained Nasdaq Capital Market approval with transfer effective May 23, 2025, and regained compliance with Nasdaq listing requirements shortly thereafter [N5][N6].
• The company secured a Korean patent for AZD1656, advancing its global development strategy for autoimmune disorders [N7].
• Andrew Regan was appointed CEO, succeeding David Tapolczay, indicating leadership transition [N8].

CDT Equity's use of AI-driven drug development and solid-form chemistry technologies positions it to unlock significant value from clinical-stage compounds that have been deprioritized by larger pharmaceutical companies. The company's strategic partnerships with Sarborg and Manoira enable it to expand its pipeline into both human and animal health markets, potentially broadening revenue streams. Successful pre-clinical trials guided by AI insights could lead to licensing deals with larger pharmaceutical companies, generating milestone payments and royalty income. The extension of patent life by up to 20 years through proprietary technologies enhances the commercial potential of its assets. The company's capital-efficient, lean operating model supports adaptability and speed in a competitive sector [S1][N1][N3][N4].

CDT Equity faces significant risks including its current liquidity constraints, with cash and cash equivalents of only $97,000 as of March 31, 2026, and a current ratio of 0.14, raising substantial doubt about its ability to continue as a going concern for the next 12 months. The company operates in a highly competitive and regulated pharmaceutical industry where clinical and pre-clinical trials carry inherent risks of failure. There is no assurance that pre-clinical trials will be successful or that licensing deals will materialize. Dependence on third-party suppliers and manufacturing organizations introduces supply chain risks. The company's reliance on related-party agreements, including with Sarborg and Manoira, may present conflicts of interest. Additionally, multiple reverse stock splits indicate historical share price challenges, which may affect investor perception and capital raising ability [S1][S2][N2].

CDT Equity's competitive advantage lies in its integration of advanced AI technologies and proprietary solid-form chemistry to enhance and extend the value of clinical-stage pharmaceutical assets. Its partnership with Sarborg Limited provides access to AI-powered signature analysis and decision-support tools that optimize drug development and asset management, potentially accelerating timelines and reducing costs. The company's ability to extend patent life by up to 20 years through co-crystallization and solid-form technologies further strengthens its intellectual property position. Additionally, CDT's lean, asset-agnostic model allows for capital-efficient operations by avoiding costly late-stage clinical trials. Exclusive licensing agreements with AstraZeneca for key clinical assets provide a foundation for pipeline development. These factors collectively create barriers to entry and differentiation in a competitive pharmaceutical development landscape [S1][N1][N3].

• Liquidity Risk: As of March 31, 2026, the company had only $97,000 in cash and cash equivalents with a current ratio of 0.14, raising substantial doubt about its ability to continue as a going concern for at least the next 12 months [S2].
• Clinical Development Risk: There is no assurance that pre-clinical or clinical trials on the company's assets will be successful, which could impact the ability to license or commercialize these assets [S1].
• Supply Chain and Manufacturing Risk: The company relies on third-party suppliers and manufacturers for clinical asset production, which may face disruptions, regulatory issues, or capacity constraints [S1].
• Regulatory and Compliance Risk: Pharmaceutical development is subject to extensive regulations; failure to comply could result in penalties or delays [S1].
• Related Party Transactions Risk: Partnerships with related parties such as Sarborg and Manoira may present conflicts of interest and governance challenges [S1].
• Market and Competitive Risk: The pharmaceutical industry is highly competitive with rapid technological changes and pricing pressures from generics and reimbursement policies [S1][S2].

• CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., is a data-driven pharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships [S1].
• The company leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate development of novel treatments [S1].
• Its strategy centers on unlocking value of clinical-stage compounds deprioritized by larger pharmaceutical companies, particularly those with strong Phase I safety data [S1].
• CDT uses advanced co-crystallization and solid-form technologies developed at its Cambridge facilities to improve drug properties and extend patent life by up to 20 years [S1].
• The company partners with Sarborg Limited, applying AI-powered signature analysis to identify new therapeutic applications and combinations for existing compounds [S1].
• The pipeline targets autoimmune disorders, idiopathic male infertility, oncology, dermatology, rare diseases, and animal health [S1].
• Ongoing in vitro and in vivo studies are guided by AI insights to support licensing and commercialization partnerships [S1].
• CDT operates a lean, asset-agnostic model prioritizing speed, adaptability, and capital efficiency, avoiding costs of early and late-stage clinical trials [S1].
• The company holds exclusive rights to develop clinical assets AZD1656 and AZD5658 in all human indications and AZD5904 in idiopathic male infertility, licensed from AstraZeneca [S1].
• AZD1656 has undergone Phase I and Phase II clinical trials with no significant safety signals; efficacy showed initial improvement in glucose control that deteriorated over time [S1].
• AZD5658 completed a Phase I study assessing safety and pharmacokinetics with no deaths or serious adverse events; most common adverse events were mild hypoglycemia and diarrhea [S1].
• AZD5904 underwent five Phase I studies with no expected adverse drug reactions or clinically significant changes in vital signs [S1].
• The company entered a Services Agreement with Sarborg Limited to provide algorithmic and cybernetic technology services, including decision-support tools and advanced cybernetic systems to enhance decision-making and maximize pharmaceutical asset portfolio value [S1].
• Sarborg has completed all phases and milestones under the Services Agreement, delivering dashboards and predictive models to support CDT's growth [S1].
• CDT entered a joint development agreement with Manoira Corporation to explore animal health market opportunities using licensed pharmaceutical compounds, retaining 100% ownership of human application data and IP [S1].
• The company completed multiple reverse stock splits, including a 1-for-8 split effective October 10, 2025 [N2][S1].
• As of March 31, 2026, CDT had cash and cash equivalents of $97,000, current assets of $3.05 million, and current liabilities of $21.6 million, resulting in a current ratio of 0.14 and a cash ratio of 0.03 [S2].
• For the three months ended March 31, 2026, CDT reported a net loss of $4.06 million and basic and diluted net loss per share of $5.56 [S2].
• The company has an accumulated deficit of $72.4 million as of March 31, 2026 [S2].
• Management has determined there is substantial doubt about the company's ability to continue as a going concern for at least the next 12 months due to insufficient cash and liquidity [S2].
• CDT Equity announced plans to buy a 20% stake in Sarborg to expand AI offerings [N1].
• Conduit Pharmaceuticals filed patents for AZD5658 and new combination patents for AZD1656 and AZD5658 in collaboration with Sarborg Limited [N3].
• Conduit Pharma entered a joint development deal with Manoira to enter the animal health market [N4].
• Conduit Pharma gained Nasdaq Capital Market approval with transfer effective May 23, 2025 [N5].
• Conduit Pharmaceuticals regained compliance with Nasdaq listing requirements as of May 21, 2025 [N6].
• Conduit Pharmaceuticals secured a Korean patent for AZD1656, advancing its global development strategy for autoimmune disorders [N7].
• Conduit Pharma appointed Andrew Regan as CEO succeeding David Tapolczay [N8].